Tetrabenazine
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB04844 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | polycystic kidney disease 3 with or without polycystic liver disease | KG + DL |
| 2 | renal-hepatic-pancreatic dysplasia | KG + DL |
| 3 | Joubert syndrome with renal defect | KG + DL |
| 4 | karyomegalic interstitial nephritis | KG + DL |
| 5 | thoracic malformation | KG + DL |
| 6 | polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | KG + DL |
| 7 | acute intermittent porphyria | KG + DL |
| 8 | adult familial nephronophthisis-spastic quadriparesia syndrome | KG + DL |
| 9 | atypical glycine encephalopathy | KG + DL |
| 10 | congenital disorder of glycosylation with defective fucosylation | KG + DL |
| 11 | retinal dystrophy with or without extraocular anomalies | KG + DL |
| 12 | myopia X-linked | KG + DL |
| 13 | myopia 26, X-linked, female-limited | KG + DL |
| 14 | Charcot-Marie-Tooth disease, demyelinating, type 1G | KG + DL |
| 15 | schizophrenia | KG + DL |
| 16 | syndromic myopia | KG + DL |
| 17 | hydranencephaly (disease) | KG + DL |
| 18 | polycystic kidney disease | KG + DL |
| 19 | glutaric acidemia type 3 | KG + DL |
| 20 | juvenile onset Parkinson disease 19A | KG + DL |
| 21 | tubular renal disease-cardiomyopathy syndrome | KG + DL |
| 22 | cardiomyopathy-cataract-hip spine disease syndrome | KG + DL |
| 23 | isobutyryl-CoA dehydrogenase deficiency | KG + DL |
| 24 | metal transport or utilization disorder with epilepsy | KG + DL |
| 25 | PLA2G6-associated neurodegeneration | KG + DL |
| 26 | hereditary late onset Parkinson disease | KG + DL |
| 27 | X-linked hereditary sensory and autonomic neuropathy with deafness | KG + DL |
| 28 | Joubert syndrome with oculorenal defect | KG + DL |
| 29 | psychogenic movement disorders | KG + DL |
| 30 | tremor-nystagmus-duodenal ulcer syndrome | KG + DL |
| 31 | primary orthostatic tremor | KG + DL |
| 32 | Hirschsprung disease | KG + DL |
| 33 | benign paroxysmal tonic upgaze of childhood with ataxia | KG + DL |
| 34 | Meckel syndrome, | KG + DL |
| 35 | paralysis agitans, juvenile, of Hunt | KG + DL |
| 36 | spinocerebellar ataxia 42, early-onset, severe, with neurodevelopmental deficits | KG + DL |
| 37 | neurodegenerative disease with chorea | KG + DL |
| 38 | miscellaneous movement disorder due to neurodegenerative disease | KG + DL |
| 39 | atypical juvenile parkinsonism | KG + DL |
| 40 | disorder of iron metabolism and transport | KG + DL |
| 41 | chronic tic disorder | KG + DL |
| 42 | extrapyramidal and movement disease | KG + DL |
| 43 | benign shuddering attacks | KG + DL |
| 44 | Ambras type hypertrichosis universalis congenita | KG + DL |
| 45 | Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome | KG + DL |
| 46 | familial amyotrophic lateral sclerosis | KG + DL |
| 47 | familial congenital mirror movements | KG + DL |
| 48 | childhood-onset benign chorea with striatal involvement | KG + DL |
| 49 | neuroacanthocytosis | KG + DL |
| 50 | lethal infantile mitochondrial myopathy | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.